Kindbiotechnology
1 known investors
Kind Biotechnology develops the ION platform, which uses artificial genomic constructs to grow interconnected peripheral organs for xenotransplantation. The company aims to address organ scarcity in transplant medicine to treat age-related organ failure and extend healthy human lifespan.
BiotechLongevityMedical Devices